Navigating AI Regulations in Healthcare: A Dynamic Approach

The regulatory landscape for artificial intelligence (AI) in healthcare is rapidly changing, particularly as Europe and the UK follow different paths. Organizations in the medical sector face the challenge of ensuring that AI tools remain compliant through their continuous evolution and updates.

The Necessity of Ongoing Compliance

When a hospital invests in an AI solution designed for a specific task, it often encounters significant modifications in subsequent versions of the product. These updates can introduce new functionalities that may alter the tool's output, the decisions it guides, and the personnel responsible for overseeing its use. Therefore, regulation needs to be interpreted in the context of the product's lifecycle, not solely from documents presented at the time of purchase.

Key regulatory changes are set to take place by October 2026. The EU’s AI Act has been revised, and the UK Government is advancing a program aimed at regulating healthcare AI. While these developments are critical, they do not establish a unified approval process across Europe nor eliminate existing medical device obligations.

Changes to EU Regulations

The AI Omnibus, officially known as Regulation (EU) 2026/1744, became effective on July 27, 2026. This regulation changes previous deadlines related to high-risk requirements, now extending them to December 2, 2027, for systems under Article 6(2) and Annex III, and to August 2, 2028, for systems classified under Article 6(1) and Annex I.

With these adjustments, the European Commission has provided clear timelines and accompanying modifications to governance, testing, and administrative processes. It is crucial for procurement and development teams to keep updated with these changes, as old timelines indicating earlier deadlines can lead to confusion.

Although deadlines have been extended, medical products still need to adhere to existing medical-device regulations, as the new timeline applies only to specific regulations. Organizations must be clear about the intended use of their products and ensure they meet all current conformity obligations.

Understanding Product Classification

The European guidance on medical devices combined with the AI Act clarifies the pathway to high-risk classification for AI tools. According to Article 6(1), an AI application must meet certain criteria to be regulated as a medical device, including requiring third-party conformity assessments. This classification process is distinct from the risk classifications ascribed to medical devices.

In this context, simply using AI in medical settings or labeling it clinical software does not automatically resolve its regulatory classification. Moreover, AI applications can be standalone medical-device software that’s not embedded in other machinery. The distinctions laid out in the guidance from June 2025 are still pertinent, even as timelines evolve.

To ensure clarity, descriptions of what the AI system is designed to accomplish should explicitly outline the types of data it handles and how this information impacts patient care. For example, an AI tool that organizes administrative tasks should be treated differently than one that recommends treatments.

The UK’s Regulatory Reform Program

On October 6, 2026, the UK Government endorsed all 44 recommendations from the National Commission on AI in Healthcare Regulation. This commitment focuses on a risk-based approach with ongoing oversight during a product's lifecycle, involving various stakeholders—regulators, health services, industry, and patients.

Understanding the phased nature of these reforms is essential for AI developers as they navigate their go-to-market strategies. While recommended changes signal future directions, existing products must still comply with current regulations. Therefore, it is critical for healthcare institutions to identify necessary information from manufacturers throughout the lifecycle of AI deployments.

Effective preparations involve requesting advance notices of significant changes, understanding the evidence that supports new functionalities, and establishing clear channels for addressing unexpected system behavior.

Implications of Functionality Changes

Changes in an AI tool’s functionalities are crucial considerations for compliance. For instance, the MHRA’s guidance released in July 2026 differentiates between transcription or summarization tasks and those with a specific medical purpose. Simply utilizing AI in a healthcare context does not inherently classify all products as medical devices.

As features evolve—like integrating diagnostic suggestions into a documentation tool—hospitals need to be vigilant. They must precisely understand what updates have been made, who can access new functionalities, and what evidence supports these expansions. Treating each update as just routine maintenance can obscure significant changes in a system’s classification.

Furthermore, local modifications that alter data input or how outputs reach clinicians may shift compliance requirements. Therefore, it is imperative for organizations to maintain thorough records detailing the current configurations used in practice associated with the AI technologies.

Ensuring Effective Monitoring and Adaptability

Post-market surveillance is increasingly important, and for healthcare AI tools, monitoring should link reported issues with specific product versions and settings. This approach enables organizations to trace the source of any problems, whether they stem from performance, changes in clinician usage, or exposure to different patient populations.

Plans for addressing concerns must be clear, specifying how issues are communicated to manufacturers and what steps are taken to ensure continuous patient care while any function is paused for review. These operational arrangements should clarify how they align with regulatory obligations.

In summary, as the landscape of healthcare AI continues to shift, organizations will benefit from a proactive approach in understanding regulation throughout a product's life cycle. Continuous engagement with evolving guidelines will help ensure compliance and enhance patient safety.